Neos Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare Conference
February 16 2017 - 07:30AM
Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company
focused on developing, manufacturing and commercializing innovative
extended-release (XR) products using its proprietary
modified-release drug delivery and orally disintegrating tablet
(ODT) technology platforms, today announced that Vipin Garg, Ph.D.,
president and chief executive officer, will participate in a
fireside chat at the upcoming RBC Capital Markets 2017 Global
Healthcare Conference on Thursday, February 23, 2017 at 10:30 a.m.
ET in New York, NY.
A live webcast of the presentation will be
available on the Investor Relations page of the company’s website
at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on
developing, manufacturing and commercializing products utilizing
its proprietary modified-release drug delivery technology
platforms. Adzenys XR-ODTTM, indicated for the treatment of ADHD in
patients 6 years of age and older, is the first approved product
using the Company’s extended-release (XR)-orally disintegrating
tablet (ODT) technology platform. Neos, which is initially focusing
on the treatment of ADHD, has filed New Drug Applications with the
U.S. Food and Drug Administration for two other branded product
candidates that are XR medications in ODT or oral suspension dosage
forms. In addition, Neos manufactures and markets its generic
equivalent of the branded product Tussionex®, an XR oral suspension
of hydrocodone and chlorpheniramine indicated for the relief of
cough and upper respiratory symptoms of a cold.1
1Tussionex® is a registered trademark of the UCB Group of
Companies.
Contacts:
Richard Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com
Sarah McCabe
Vice President
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Mar 2023 to Mar 2024